secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001213900-25-073100
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q2 net loss $41.6M; rezpegaldesleukin Fast Track; cash runway into Q1 2027
--------------------------------------------------------------------------------

- Revenue $11.2M Q2 2025 vs $23.5M Q2 2024; decrease due to sale of Huntsville facility.
- Net loss $41.6M ($2.95 per share) vs $52.4M loss ($3.76 per share) in Q2 2024.
- Cash and investments $175.9M at June 30, 2025; excludes $107.5M net proceeds from July 2025 offering; runway into Q1 2027.
- FDA Fast Track granted for rezpegaldesleukin in severe-to-very severe alopecia areata (July 2025).
- REZOLVE-AD Phase 2b met primary and key secondary endpoints at week 16; 52-week data expected early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025073100/0001213900-25-073100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025073100/ea0252183-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-073100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer